Collaboration Agreements - Additional Information (Details) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
|
| Research And Development Arrangement Contract To Perform For Others [Line Items] | |||||
| Deferred revenue | $ 2,733,000 | $ 2,733,000 | $ 2,733,000 | ||
| Research and development expense | 10,824,000 | $ 18,130,000 | 37,894,000 | $ 53,127,000 | |
| BeiGene Agreement | |||||
| Research And Development Arrangement Contract To Perform For Others [Line Items] | |||||
| Deferred revenue | 2,700,000 | 2,700,000 | 2,700,000 | ||
| Research and development expense | 0 | 0 | 0 | 0 | |
| Incremental costs | 3,500,000 | ||||
| BeiGene Agreement | Other Assets | |||||
| Research And Development Arrangement Contract To Perform For Others [Line Items] | |||||
| Incremental costs | 200,000 | $ 200,000 | |||
| Arbutus Biopharma Agreement | |||||
| Research And Development Arrangement Contract To Perform For Others [Line Items] | |||||
| Research and development expense | $ 100,000 | $ 700,000 | $ 1,200,000 | $ 1,900,000 | |